Fairfield, Bush & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.18M | Sell |
1,532
-146
| -9% | -$112K | 0.66% | 40 |
|
|
2025
Q4 | $1.3M | Sell |
1,678
-193
| -10% | -$131K | 0.68% | 40 |
|
|
2025
Q3 | $1.05M | Sell |
1,871
-316
| -14% | -$179K | 0.54% | 45 |
|
|
2025
Q2 | $1.15M | Buy |
2,187
+30
| +1% | +$16.7K | 0.65% | 43 |
|
|
2025
Q1 | $1.37M | Buy |
2,157
+193
| +10% | +$133K | 0.87% | 36 |
|
|
2024
Q4 | $1.4M | Buy |
1,964
+125
| +7% | +$105K | 0.82% | 37 |
|
|
2024
Q3 | $1.93M | Sell |
1,839
-137
| -7% | -$152K | 1.15% | 27 |
|
|
2024
Q2 | $2.08M | Sell |
1,976
-6
| -0.3% | -$5.82K | 1.24% | 24 |
|
|
2024
Q1 | $1.91M | Sell |
1,982
-76
| -4% | -$72.3K | 1.13% | 26 |
|
|
2023
Q4 | $1.81M | Buy |
2,058
+123
| +6% | +$101K | 1.06% | 27 |
|
|
2023
Q3 | $1.59M | Buy |
1,935
+115
| +6% | +$90.4K | 1.04% | 28 |
|
|
2023
Q2 | $1.31M | Buy |
1,820
+95
| +6% | +$73.2K | 0.36% | 60 |
|
|
2023
Q1 | $1.42M | Sell |
1,725
-245
| -12% | -$185K | 0.5% | 50 |
|
|
2022
Q4 | $1.42M | Buy |
1,970
+171
| +10% | +$126K | 0.94% | 28 |
|
|
2022
Q3 | $1.24M | Buy |
1,799
+155
| +9% | +$97.6K | 0.87% | 31 |
|
|
2022
Q2 | $972K | Sell |
1,644
-170
| -9% | -$111K | 0.57% | 42 |
|
|
2022
Q1 | $1.27M | Sell |
1,814
-637
| -26% | -$403K | 0.64% | 40 |
|
|
2021
Q4 | $1.55M | Sell |
2,451
-50
| -2% | -$30.7K | 0.74% | 35 |
|
|
2021
Q3 | $1.51M | Sell |
2,501
-245
| -9% | -$152K | 0.49% | 53 |
|
|
2021
Q2 | $1.53M | Buy |
2,746
+1,292
| +89% | +$655K | 0.42% | 52 |
|
|
2021
Q1 | $688K | Buy |
1,454
+565
| +64% | +$275K | 0.2% | 96 |
|
|
2020
Q4 | $429K | Sell |
889
-496
| -36% | -$268K | 0.13% | 113 |
|
|
2020
Q3 | $775K | Buy |
1,385
+805
| +139% | +$488K | 0.25% | 80 |
|
|
2020
Q2 | $362K | Buy |
+580
| New | +$329K | 0.13% | 102 |
|
|
2017
Q4 | – | Sell |
-500
| Closed | -$224K | – | 160 |
|
|
2017
Q3 | $224K | Hold |
500
| – | – | 0.07% | 137 |
|
|
2017
Q2 | $246K | Buy |
+500
| New | +$219K | 0.08% | 130 |
|
|
2016
Q4 | – | Sell |
-500
| Closed | -$201K | – | 151 |
|
|
2016
Q3 | $201K | Buy |
+500
| New | +$201K | 0.07% | 144 |
|
|
2016
Q1 | – | Sell |
-500
| Closed | -$271K | – | 139 |
|
|
2015
Q4 | $271K | Hold |
500
| – | – | 0.09% | 120 |
|
|
2015
Q3 | $233K | Hold |
500
| – | – | 0.1% | 116 |
|
|
2015
Q2 | $255K | Hold |
500
| – | – | 0.08% | 147 |
|
|
2015
Q1 | $226K | Hold |
500
| – | – | 0.07% | 160 |
|
|
2014
Q4 | $205K | Buy |
+500
| New | +$197K | 0.06% | 168 |
|
Other funds holding REGN
VCM
N
Fairfield, Bush & Co's REGN Position: Q1 2026 in Review
Fairfield, Bush & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 8.7% in Q1 2026, selling an estimated $112K and leaving 1,532 shares worth $1.18M. The position accounts for 0.66% of the portfolio, ranked #40.
Fairfield, Bush & Co first reported a position in REGN in Q4 2014 and has held it in 32 quarters since. The position peaked at $2.08M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Fairfield, Bush & Co held 1,532 shares of Regeneron Pharmaceuticals worth $1.18M as of Q1 2026.
- Fairfield, Bush & Co sold 146 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $112K.
- Regeneron Pharmaceuticals made up 0.66% of Fairfield, Bush & Co's portfolio in Q1 2026, its #40 holding.
- Fairfield, Bush & Co first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 32 quarters since.
- Fairfield, Bush & Co's Regeneron Pharmaceuticals position peaked at $2.08M in Q2 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.